JPH01500435A - 先端的抗癌療法及びその実施のための細胞毒性薬物 - Google Patents

先端的抗癌療法及びその実施のための細胞毒性薬物

Info

Publication number
JPH01500435A
JPH01500435A JP62504770A JP50477087A JPH01500435A JP H01500435 A JPH01500435 A JP H01500435A JP 62504770 A JP62504770 A JP 62504770A JP 50477087 A JP50477087 A JP 50477087A JP H01500435 A JPH01500435 A JP H01500435A
Authority
JP
Japan
Prior art keywords
composition
cytotoxic
cells
conjugate
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62504770A
Other languages
English (en)
Japanese (ja)
Inventor
マイアーズ　アンドリュー
ビション　ダニエル
Original Assignee
イントラセル　コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イントラセル　コーポレイション filed Critical イントラセル　コーポレイション
Publication of JPH01500435A publication Critical patent/JPH01500435A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP62504770A 1986-08-07 1987-08-05 先端的抗癌療法及びその実施のための細胞毒性薬物 Pending JPH01500435A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP86810347.4 1986-08-07
EP86810347 1986-08-07

Publications (1)

Publication Number Publication Date
JPH01500435A true JPH01500435A (ja) 1989-02-16

Family

ID=8196463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62504770A Pending JPH01500435A (ja) 1986-08-07 1987-08-05 先端的抗癌療法及びその実施のための細胞毒性薬物

Country Status (10)

Country Link
US (1) US5087616A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0259904B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH01500435A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU608531B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1323303C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3770730D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK184788A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI881579A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN165717B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1988000837A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN165717B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US5529932A (en) * 1988-01-28 1996-06-25 Pharmacia, S.P.A. Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
DE4004573A1 (de) * 1989-02-17 1990-08-23 Tanabe Seiyaku Co Neues versuchstier und seine herstellung
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5576288A (en) * 1989-04-27 1996-11-19 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
HU219336B (en) * 1989-07-20 2001-03-28 Novartis Ag Process for producing peptide derivatives and pharmaceutical compositions comprising such compounds and diagnostic unit containing such compounds
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
CA2070416A1 (en) * 1989-10-23 1991-04-24 Richard Ingram Polypeptide inhibitors of gamma interferon
DK0517829T4 (da) * 1990-03-02 2008-03-03 Boston Medical Ct Corp Forbedrede kimæriske toksiner
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
WO1991018630A1 (de) * 1990-05-30 1991-12-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Polyethersubstituierte tumormittel
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
WO1992000762A1 (en) * 1990-07-05 1992-01-23 Akzo N.V. Receptor directed-toxin conjugates
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5431899A (en) * 1991-02-04 1995-07-11 University Of Saskatchewan Rotavirus VP6 as a diagnostic and targeting agent
US5464753A (en) * 1991-03-08 1995-11-07 Univ Illinois Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
CA2106079C (en) * 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
AU662155B2 (en) * 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
ES2075402T3 (es) * 1991-07-22 1995-10-01 Bracco Int Bv Conjugados quelados con metales paramagneticos para enfoque deliberado.
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
DK0563475T3 (da) * 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
ES2143504T3 (es) * 1992-05-28 2000-05-16 Univ Toledo Uso de un material citotoxico acoplado a un material inhibidor del activador plasminogeno para la produccion de un medicamento para el tratamiento de celulas cancerigenas.
US5679350A (en) * 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
AU685058B2 (en) * 1992-06-16 1998-01-15 Selective Genetics, Inc. Recombinant production of saporin-containing proteins
US5393737A (en) * 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
ES2149823T3 (es) * 1992-09-03 2000-11-16 Univ California Factor y composiciones que afectan al tejido dorsal.
US5466672A (en) * 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US6001364A (en) * 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
EP0697891B1 (en) 1993-05-05 2000-03-29 Keith Rose Polyoxime compounds and their preparation
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US6491905B1 (en) * 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
ES2148259T3 (es) * 1993-09-22 2000-10-16 Hoechst Ag Pro-profarmacos, su produccion y uso.
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5962220A (en) * 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
DE4433890C2 (de) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
CA2204789C (en) * 1994-11-10 2002-11-12 Paul Ashton Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5766899A (en) * 1995-02-27 1998-06-16 Board Of Regents , The University Of Texas System Targeted nucleic acid delivery into liver cells
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
EP0871490B1 (en) * 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
US20050025740A1 (en) * 1996-01-05 2005-02-03 Keith Rose Polyoxime compounds and their preparation
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6080383A (en) * 1997-01-13 2000-06-27 Rose; Samuel Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
WO1998047496A2 (en) * 1997-04-18 1998-10-29 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
AU746423B2 (en) * 1997-05-05 2002-05-02 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6866837B2 (en) 1998-06-05 2005-03-15 Mallinckrodt Inc. Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
EP1098666B1 (en) * 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB9904582D0 (en) * 1999-02-26 1999-04-21 Nycomed Imaging As Process
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001249504A1 (en) * 2000-03-27 2001-10-08 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
ES2518926T3 (es) 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
CA2414650A1 (en) * 2000-06-30 2002-01-10 Board Of Regents, The University Of Texas System Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
CA2424345A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
EP1404334A4 (en) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc TARGETED ADMINISTRATION OF BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER
CA2447335C (en) * 2001-05-15 2011-01-04 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
US7067494B2 (en) * 2001-06-22 2006-06-27 The University Of British Columbia Antimitotic eleuthesides
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
WO2003072046A2 (en) * 2002-02-22 2003-09-04 New River Pharmaceuticals Inc. Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20030109432A1 (en) * 2001-12-10 2003-06-12 Zuo William W. Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
RU2196604C1 (ru) * 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
CN1650024A (zh) * 2002-02-22 2005-08-03 新河药品股份有限公司 应用肽－药物的结合减少受试者间药物血清水平的变异
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
EP1562641A4 (en) * 2002-11-07 2008-12-03 Univ Texas ETHYLENE DIOXIDE (EC) DRUG CONJUGATES, COMPOSITIONS AND METHODS FOR THE TISSUE-SPECIFIC DISPLAY OF DISEASES
CA2524350C (en) 2003-05-07 2015-04-14 Indiana University Research & Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
PT1644019E (pt) * 2003-05-29 2012-05-23 Shire Llc Compostos de anfetamina resistentes ao abuso
WO2005016368A2 (en) * 2003-08-19 2005-02-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of phosphophoryn for inducing biomineralization and bone regeneration
JP4691500B2 (ja) * 2003-09-30 2011-06-01 シャイア エルエルシー 過剰摂取又は乱用を防止するための薬学組成物
AU2004284075A1 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
WO2005055931A2 (en) 2003-12-03 2005-06-23 University Of Medicine And Dentistry Of New Jersey Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
CN100457185C (zh) * 2003-12-10 2009-02-04 株式会社东京大学Tlo 二氨基环己烷合铂(ⅱ)与含聚羧酸链段的嵌段共聚物的配位络合物、其抗肿瘤剂
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US20060036084A1 (en) * 2004-08-04 2006-02-16 Lianhua Qu Conglomerated semiconductor nanocrystals
US8454927B2 (en) * 2004-08-04 2013-06-04 Crystalplex Corporation Alloyed semiconductor nanocrystals
EP2656840B1 (en) * 2005-06-09 2015-09-16 NanoCarrier Co., Ltd. Method for producing polymerized coordination compounds of platinum complex
RU2303997C2 (ru) * 2005-09-27 2007-08-10 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Конъюгат, обладающий избирательным действием по отношению к раковым опухолям
WO2007055902A1 (en) 2005-11-03 2007-05-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides and methods of use for treating and preventing cancer
WO2007067417A1 (en) * 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
US9107863B2 (en) 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
RU2317102C1 (ru) * 2006-05-31 2008-02-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Пептид, являющийся аналогом фрагмента альфа-фетопротеина, конъюгат пептида с доксорубицином и фармацевтическая композиция на его основе для лечения онкологических заболеваний
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2431388A1 (en) 2006-10-31 2012-03-21 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Smoothened polypeptides and methods of use
AU2008206442B2 (en) * 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
CN101711284A (zh) * 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
CN104800856A (zh) * 2007-04-10 2015-07-29 日东电工株式会社 多功能聚谷氨酸盐药物载体
US20080279782A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polymers conjugated with platinum drugs
KR20100017540A (ko) 2007-05-09 2010-02-16 닛토덴코 가부시키가이샤 소수성 화합물 및 폴리아미노산 콘쥬게이트를 포함하는 조성물
WO2008141110A2 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
WO2009029844A1 (en) * 2007-08-31 2009-03-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
EP2262537A1 (en) * 2008-03-06 2010-12-22 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US9616245B2 (en) * 2009-03-16 2017-04-11 Rajah Vijay Kumar Method of treating cells with drug and radiation according to proton density
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
US8603814B2 (en) 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
US9127079B2 (en) 2009-10-16 2015-09-08 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (PTEN) conjugates
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
CA2780572A1 (en) 2009-11-13 2011-05-19 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modulated programmed death ligand-1
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
JP6133209B2 (ja) 2010-09-21 2017-05-24 アメリカ合衆国 抗ｓｓｘ−２ｔ細胞受容体及び関連材料並びに使用方法
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
CN102675422B (zh) 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
PT2694549T (pt) 2011-04-08 2018-11-22 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização do mesmo para o tratamento de cancro
CN102746378B (zh) 2011-04-22 2014-10-22 天津托普泰克生物科技有限公司 抗脂肪酸合成酶多肽及其应用
RU2627216C2 (ru) 2011-06-09 2017-08-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Экзотоксин а pseudomonas с менее иммуногенными т-и/или в-клеточными эпитопами
WO2012177443A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CN109517055B (zh) 2011-09-15 2022-09-20 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体
HK1198170A1 (en) 2011-09-16 2015-03-13 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
CN104379179A (zh) 2012-04-11 2015-02-25 美国卫生和人力服务部 靶向b-细胞成熟抗原的嵌合抗原受体
US9487573B2 (en) 2012-05-22 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Murine anti-NY-ESO-1 T cell receptors
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
ES2674946T3 (es) 2012-06-21 2018-07-05 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
LT2895509T (lt) 2012-09-14 2020-03-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T ląstelių receptoriai, atpažįstantys mhc ii klasės apribotą mage-a3
ES2718903T3 (es) 2012-10-24 2019-07-05 Us Health Receptores de antígenos quiméricos M971
ES2949648T3 (es) 2012-12-20 2023-10-02 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
WO2014205187A1 (en) 2013-06-20 2014-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
EP3572423B1 (en) 2013-07-15 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-human papillomavirus 16 e6 t cell receptors
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
WO2015084513A1 (en) 2013-12-06 2015-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
ES2784237T3 (es) 2014-05-29 2020-09-23 Us Health Receptores de células T anti-papilomavirus 16 E7 humano
WO2015187528A1 (en) 2014-06-02 2015-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting cd-19
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
SG11201703203RA (en) 2014-10-20 2017-05-30 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
US20190030071A1 (en) 2014-11-03 2019-01-31 IMMURES S.r.I. T cell receptors
TWI787903B (zh) 2014-11-05 2022-12-21 美商奇諾治療有限公司 用於轉導作用及細胞處理之方法
KR20250067192A (ko) 2014-12-03 2025-05-14 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 방법 및 조성물
TWI718118B (zh) 2015-01-16 2021-02-11 美商奇諾治療有限公司 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
EP3303586A1 (en) 2015-05-29 2018-04-11 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
KR20180108567A (ko) 2015-10-22 2018-10-04 주노 테라퓨틱스 게엠베하 형질도입을 위한 방법, 키트, 제제 및 장치
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
EP3430548A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
MA43759A (fr) 2016-03-16 2018-11-28 Jason Connor Procédés de conception adaptative d'un régime de traitement et traitements associés
CN109476743A (zh) 2016-03-22 2019-03-15 西雅图儿童医院(以西雅图儿童研究所名义营业) 预防或缓解毒性的早期干预方法
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CA3022611A1 (en) 2016-05-06 2017-11-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
EP3464366A1 (en) 2016-05-27 2019-04-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
MX2018014991A (es) 2016-06-03 2019-08-29 Memorial Sloan Kettering Cancer Center Terapias adoptivas de celulas como opciones de tratamiento temprano.
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US20190201414A1 (en) 2016-07-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
CN110087672A (zh) 2016-07-29 2019-08-02 朱诺治疗学股份有限公司 免疫调节多肽及相关组合物和方法
EP3519433A1 (en) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
EP3548084B1 (en) 2016-12-03 2023-08-23 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
BR112019011025A2 (pt) 2016-12-03 2019-10-08 Juno Therapeutics Inc métodos para modulação de células t car
BR112019011207A2 (pt) 2016-12-05 2019-10-08 Juno Therapeutics Inc produção de células modificadas para terapia celular adotiva
MX2019008227A (es) 2017-01-10 2020-08-17 Juno Therapeutics Inc Analisis epigenetico de terapia celular y metodos relacionados.
MA47325A (fr) 2017-01-20 2019-11-27 Juno Therapeutics Gmbh Conjugués de surface cellulaire et compositions cellulaires et méthodes associées
EP4501352A3 (en) 2017-02-28 2025-04-16 Endocyte, Inc. Compositions and methods for car t cell therapy
CN110730908B (zh) 2017-04-07 2025-01-21 朱诺治疗学股份有限公司 表达前列腺特异性膜抗原（psma）或其修饰形式的工程化细胞及相关方法
TW201842335A (zh) 2017-04-27 2018-12-01 德商朱諾醫療公司 寡聚粒子試劑及其使用方法
US11740231B2 (en) 2017-06-02 2023-08-29 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
MX2020003536A (es) 2017-10-03 2020-09-14 Juno Therapeutics Inc Moleculas de union especifica a virus de papiloma humano (hpv).
DK3704230T3 (da) 2017-11-01 2025-01-02 Juno Therapeutics Inc Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler
MX2020004239A (es) 2017-11-01 2020-09-09 Juno Therapeutics Inc Proceso para producir una composicion de celulas t.
MA50860A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
AU2018358250B2 (en) 2017-11-01 2025-06-05 Editas Medicine, Inc. Methods, compositions and components for CRISPR-CAS9 editing of TGFBR2 in T cells for immunotherapy
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
KR20200079312A (ko) 2017-11-06 2020-07-02 에디타스 메디신, 인코포레이티드 면역요법을 위한 t 세포 내 cblb의 crispr-cas9 편집 방법, 조성물 및 성분
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
MA51105A (fr) 2017-12-08 2020-10-14 Juno Therapeutics Inc Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
SG11202005217VA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Phenotypic markers for cell therapy and related methods
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
WO2019152743A1 (en) 2018-01-31 2019-08-08 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US20210046159A1 (en) 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
MA52207A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
WO2019195486A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CA3108698A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
AU2019328677A1 (en) 2018-08-31 2021-04-01 Invectys SA Chimeric antigen receptors against multiple HLA-G isoforms
AU2019370705A1 (en) 2018-10-31 2021-05-27 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
CA3116413A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
JP7604366B2 (ja) 2018-11-06 2024-12-23 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作されたｔ細胞を作製するための方法
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
EP4393547A3 (en) 2018-11-30 2024-09-18 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
CN113710256A (zh) 2018-11-30 2021-11-26 朱诺治疗学股份有限公司 使用过继细胞疗法的治疗方法
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
WO2020210719A1 (en) 2019-04-10 2020-10-15 Elevatebio Management, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
CN113811329A (zh) 2019-04-19 2021-12-17 天科雅生物科技有限公司 抗pd-1抗体和其用途
EP3962519A1 (en) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
EP3972653A1 (en) 2019-05-22 2022-03-30 Massachusetts Institute of Technology Circular rna compositions and methods
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
US20250237628A1 (en) 2019-10-30 2025-07-24 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
JP7605840B2 (ja) 2019-12-06 2024-12-24 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法
AU2021214142A1 (en) 2020-01-28 2022-09-08 Juno Therapeutics, Inc. Methods for T cell transduction
IL297147A (en) 2020-04-10 2022-12-01 Juno Therapeutics Inc Methods and Uses Related to Transgenic Cell Therapy with a Chimeric Antigen Receptor Directed to a B-Cell Maturation Antigen
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
CN116322788A (zh) 2020-05-19 2023-06-23 奥纳治疗公司 环状rna组合物和方法
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
KR20240112994A (ko) 2021-11-03 2024-07-19 셀진 코포레이션 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
KR20240107139A (ko) 2021-11-08 2024-07-08 오나 테라퓨틱스, 인코포레이티드 원형 폴리뉴클레오티드를 전달하기 위한 지질 나노입자 조성물
JP2025508783A (ja) 2022-02-22 2025-04-10 ジュノー セラピューティクス インコーポレイテッド プロテイナーゼ３（ｐｒ３）キメラ自己抗体受容体ｔ細胞ならびに関連する方法および使用
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
EP4547230A1 (en) 2022-06-29 2025-05-07 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38892B1 (en) * 1973-03-28 1978-06-21 Ici Ltd Pharmaceutical compositions
EP0040506B1 (en) * 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
IE53166B1 (en) * 1980-08-05 1988-08-03 Searle & Co Synthetic urogastrone gene,corresponding plasmid recombinants,transformed cells,production thereof and urogastrone expression
EP0108132A1 (en) * 1982-05-06 1984-05-16 Applied Molecular Genetics Inc. The manufacture and expression of genes for urogastrone and polypeptide analogs thereof
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
JPS58219124A (ja) * 1982-06-15 1983-12-20 Nippon Chem Res Kk ヒト上皮細胞増殖因子の製造法
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
EP0148922A4 (en) * 1983-07-05 1987-06-15 Chiron Corp SYNTHESIS USING HYBRID EPIDERMAL GROWTH FACTOR DNA.
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
IL69719A0 (en) * 1983-09-14 1983-12-30 Yeda Res & Dev Synthetic peptides with egf like activity
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
US4670563A (en) * 1984-06-20 1987-06-02 Sanofi Imidazolides as intermediates for the synthesis of cytotoxic conjugates
IN165717B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1986-08-07 1989-12-23 Battelle Memorial Institute

Also Published As

Publication number Publication date
DK184788A (da) 1988-06-06
WO1988000837A2 (en) 1988-02-11
EP0259904A1 (en) 1988-03-16
CA1323303C (en) 1993-10-19
IN165717B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-12-23
EP0259904B1 (en) 1991-06-12
FI881579A7 (fi) 1988-04-06
WO1988000837A3 (en) 1988-03-10
AU7788787A (en) 1988-02-24
DE3770730D1 (de) 1991-07-18
US5087616A (en) 1992-02-11
AU608531B2 (en) 1991-04-11
FI881579L (fi) 1988-04-06
DK184788D0 (da) 1988-04-06
FI881579A0 (fi) 1988-04-06

Similar Documents

Publication Publication Date Title
JPH01500435A (ja) 先端的抗癌療法及びその実施のための細胞毒性薬物
AU2020200975B2 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
US20080167370A1 (en) Multidrug multiligand conjugates for targeted drug delivery
AU4094300A (en) Amplification of folate-mediated targeting to tumor cells using polymers
JP2003506319A (ja) ビタミンに関連したデュアルターゲッティング治療法
WO1995001806A1 (en) Pro-cytotoxic drug conjugates for anticancer therapy
JPH10502334A (ja) 受容体調節剤およびこれに関連した方法
CA1222694A (en) Immunochemotherapy for malignant tumors, particularly pancreatic cancer
JP2002511857A (ja) 抗体−酵素複合体をプロドラッグと組合せて含む薬学的組成物
EP1463529B9 (en) Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
US6727347B1 (en) Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body
AU2002362210B8 (en) Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates
US20050220754A1 (en) Vitamin directed targeting therapy
Connors Selectivity in cancer chemotherapy
CN118580336A (zh) 一种白蛋白偶联物及其制备方法和应用
AU2004201277A1 (en) Amplification of folate-mediated targeting to tumor cells using polymers